Direct Flow attracts $27m from Johnson & Johnson et al:
This article was originally published in Clinica
Direct Flow Medical, a company developing a percutaneous heart valve replacement system, has bagged $27m in a series B financing co-led by Johnson & Johnson's investment arm and Foundation Medical Partners. Vantage Point Venture Partners and ePlanet - two new investors - also participated in the round, together with existing shareholders EDF Ventures, New Lead Venture Partners and Spray Venture Partners. Direct Flow's catheter-based system provides doctors with a minimally-invasive, transfemoral approach to replace diseased heart valve with a pericardial tissue implant. The Santa Rosa, California company initiated its European clinical study in September, following a first-in-man in Germany.
You may also be interested in...
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.